- Home
- SONO vs AKRO Comparison
SONO vs AKRO Comparison
Compare SONO & AKRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SONO
- AKRO
- Stock Information
- Founded
- SONO 2002
- AKRO 2017
- Country
- SONO United States
- AKRO United States
- Employees
- SONO N/A
- AKRO N/A
- Industry
- SONO Consumer Electronics/Video Chains
- AKRO Biotechnology: Pharmaceutical Preparations
- Sector
- SONO Consumer Discretionary
- AKRO Health Care
- Exchange
- SONO Nasdaq
- AKRO Nasdaq
- Market Cap
- SONO 1.4B
- AKRO 2.1B
- IPO Year
- SONO 2018
- AKRO 2019
- Fundamental
- Price
- SONO $12.96
- AKRO $31.59
- Analyst Decision
- SONO Hold
- AKRO Strong Buy
- Analyst Count
- SONO 3
- AKRO 7
- Target Price
- SONO $15.67
- AKRO $43.20
- AVG Volume (30 Days)
- SONO 1.3M
- AKRO 441.5K
- Earning Date
- SONO 11-13-2024
- AKRO 11-11-2024
- Dividend Yield
- SONO N/A
- AKRO N/A
- EPS Growth
- SONO N/A
- AKRO N/A
- EPS
- SONO N/A
- AKRO N/A
- Revenue
- SONO $1,567,823,000.00
- AKRO N/A
- Revenue This Year
- SONO N/A
- AKRO N/A
- Revenue Next Year
- SONO N/A
- AKRO N/A
- P/E Ratio
- SONO N/A
- AKRO N/A
- Revenue Growth
- SONO N/A
- AKRO N/A
- 52 Week Low
- SONO $10.10
- AKRO $11.36
- 52 Week High
- SONO $19.76
- AKRO $37.00
- Technical
- Relative Strength Index (RSI)
- SONO 60.67
- AKRO 66.34
- Support Level
- SONO $12.76
- AKRO $29.34
- Resistance Level
- SONO $13.19
- AKRO $32.15
- Average True Range (ATR)
- SONO 0.36
- AKRO 1.26
- MACD
- SONO 0.06
- AKRO 0.10
- Stochastic Oscillator
- SONO 93.84
- AKRO 99.74
About SONO Sonos Inc.
Sonos Inc is engaged in providing home sound systems. The company's product profile includes speaker sets and other accessories like boost, mounts, stands, and cables and networking. Geographically, the company operates in the Americas, Europe, the Middle East and Africa, and the Asia Pacific. Generating a majority of its revenue from the Americas.
About AKRO Akero Therapeutics Inc.
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis, or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that has the potential to address the core processes underlying NASH pathogenesis.